Skip to Main Content

Author Details

Christopher C Porter
Emory University School of Medicine
2003
61
24
PMIDPaper TitleJournal TitlePublished Year
37208357YB1 modulates the DNA damage response in medulloblastoma.Sci Rep2023
37798266Single-cell analysis reveals altered tumor microenvironments of relapse- and remission-associated pediatric acute myeloid leukemia.Nat Commun2023
37322047Author Correction: YB1 modulates the DNA damage response in medulloblastoma.Sci Rep2023
34385604Thrombopoietin-based CAR-T cells demonstrate in vitro and in vivo cytotoxicity to MPL positive acute myelogenous leukemia and hematopoietic stem cells.Gene Ther2022
35803545Germline ETV6 mutation promotes inflammation and disrupts lymphoid development of early hematopoietic progenitors.Exp Hematol2022
35544730Comprehensive Genomic Profiling of High-Risk Pediatric Cancer Patients Has a Measurable Impact on Clinical Care.JCO Precis Oncol2022
35785415Acute myeloid leukemia and dilated cardiomyopathy in a pediatric patient with D-2-hydroxyglutaric aciduria type I.Am J Med Genet A2022
36001348Collaboration to Promote Research and Improve Clinical Care in the Evolving Field of Childhood Cancer Predisposition.Cancer Prev Res (Phila)2022
35241678Obesity-induced galectin-9 is a therapeutic target in B-cell acute lymphoblastic leukemia.Nat Commun2022
33480151Interleukin-37 improves T-cell-mediated immunity and chimeric antigen receptor T-cell therapy in aged backgrounds.Aging Cell2021
33583498Cancer Predisposition in Neonates and Infants: Recognition, Tumor Types, and Surveillance.Clin Perinatol2021
33690997Engineered Cytokines for Cancer and Autoimmune Disease Immunotherapy.Adv Healthc Mater2021
34192286The RADx Tech Test Verification Core and the ACME POCT in the Evaluation of COVID-19 Testing Devices: A Model for Progress and Change.IEEE Open J Eng Med Biol2021
33179831Cancer genetic counseling for childhood cancer predisposition is associated with improved levels of knowledge and high satisfaction in parents.J Genet Couns2021
32195191Increased HDAC Activity and c-MYC Expression Mediate Acquired Resistance to WEE1 Inhibition in Acute Leukemia.Front Oncol2020
32786324Rapid Assembly and Screening of Multivalent Immune Cell-Redirecting Therapies for Leukemia.ACS Comb Sci2020
32841218ETV6 germline mutations cause HDAC3/NCOR2 mislocalization and upregulation of interferon response genes.JCI Insight2020
32487806Germline mutations: many roles in leukemogenesis.Curr Opin Hematol2020
32374589Optical Control of Cytokine Signaling via Bioinspired, Polymer-Induced Latency.Biomacromolecules2020
31170028Stopping Leukemia in Its Tracks: Should Preemptive Hematopoietic Stem-Cell Transplantation be Offered to Patients at Increased Genetic Risk for Acute Myeloid Leukemia?J Clin Oncol2019
31722205Mass Cytometry Reveals Global Immune Remodeling with Multi-lineage Hypersensitivity to Type I Interferon in Down Syndrome.Cell Rep2019
31648317ClinGen Myeloid Malignancy Variant Curation Expert Panel recommendations for germline RUNX1 variants.Blood Adv2019
29875418Macrocytic anemia in Lesch-Nyhan disease and its variants.Genet Med2019
31414239Germline Genetics and Childhood Cancer: Emerging Cancer Predisposition Syndromes and Psychosocial Impacts.Curr Oncol Rep2019
31248877ETV6-related thrombocytopenia and leukemia predisposition.Blood2019
31142509IL12 Abrogates Calcineurin-Dependent Immune Evasion during Leukemia Progression.Cancer Res2019
29175378Increased activity of both CDK1 and CDK2 is necessary for the combinatorial activity of WEE1 inhibition and cytarabine.Leuk Res2018
30216339Activating PAX gene family paralogs to complement PAX5 leukemia driver mutations.PLoS Genet2018
31595227The genetic risk of second cancers: should the therapy for acute lymphoblastic leukemia be individualized according to germline genetic makeup?Expert Rev Precis Med Drug Dev2018
28655785A Small-Molecule Inhibitor of WEE1, AZD1775, Synergizes with Olaparib by Impairing Homologous Recombination and Enhancing DNA Damage and Apoptosis in Acute Leukemia.Mol Cancer Ther2017
28108622A Genome-Wide Loss-of-Function Screen Identifies SLC26A2 as a Novel Mediator of TRAIL Resistance.Mol Cancer Res2017
28982143IFN-γ alters the expression of diverse immunity related genes in a cell culture model designed to represent maturing neutrophils.PLoS One2017
28572264Recommendations for Childhood Cancer Screening and Surveillance in DNA Repair Disorders.Clin Cancer Res2017
28572263Recommendations for Surveillance for Children with Leukemia-Predisposing Conditions.Clin Cancer Res2017
28674120Surveillance Recommendations for Children with Overgrowth Syndromes and Predisposition to Wilms Tumors and Hepatoblastoma.Clin Cancer Res2017
28674119Cancer Screening Recommendations and Clinical Management of Inherited Gastrointestinal Cancer Syndromes in Childhood.Clin Cancer Res2017
26909599Genome-wide functional genetic screen with the anticancer agent AMPI-109 identifies PRL-3 as an oncogenic driver in triple-negative breast cancers.Oncotarget2016
27913495Germ line mutations associated with leukemias.Hematology Am Soc Hematol Educ Program2016
25807284Germline mutations in ETV6 are associated with thrombocytopenia, red cell macrocytosis and predisposition to lymphoblastic leukemia.Nat Genet2015
26334102AZD1775 sensitizes T cell acute lymphoblastic leukemia cells to cytarabine by promoting apoptosis over DNA repair.Oncotarget2015
26324703MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemia.Blood2015
26317224INF-γ Enhances Nox2 Activity by Upregulating phox Proteins When Applied to Differentiating PLB-985 Cells but Does Not Induce Nox2 Activity by Itself.PLoS One2015
26219557ETV6 mutations define a new cancer predisposition syndrome.Oncotarget2015
24590058STAT3-mediated autophagy dependence identifies subtypes of breast cancer where autophagy inhibition can be efficacious.Cancer Res2014
24891015Inhibition of calcineurin combined with dasatinib has direct and indirect anti-leukemia effects against BCR-ABL1(+) leukemia.Am J Hematol2014
23369685Targeting developmental pathways in children with cancer: what price success?Lancet Oncol2013
24121103Inhibition of Wee1 sensitizes cancer cells to antimetabolite chemotherapeutics in vitro and in vivo, independent of p53 functionality.Mol Cancer Ther2013
23555045Knockdown of HPRT for selection of genetically modified human hematopoietic progenitor cells.PLoS One2013
22289989Integrated genomic analyses identify WEE1 as a critical mediator of cell fate and a novel therapeutic target in acute myeloid leukemia.Leukemia2012
22738915Tankyrase and the canonical Wnt pathway protect lung cancer cells from EGFR inhibition.Cancer Res2012
  • 1 - 50 of 61

Recommended Authors

Thai Hoa Tran
Universite de Montreal
Career Start Year 2013
Number of shared co-authors 3
Anagha Deshpande
Sanford Burnham Prebys Medical Discovery Institute
Career Start Year 2009
Number of shared co-authors 0
Kara L Davis
Stanford University School of Medicine
Career Start Year 2008
Number of shared co-authors 3
Amanda Winters
University of Colorado School of Medicine
Career Start Year 2008
Number of shared co-authors 5
Yana Pikman
Dana Farber Cancer Institute
Career Start Year 2005
Number of shared co-authors 2
Marlise R Luskin
Dana-Farber Cancer Institute
Career Start Year 2005
Number of shared co-authors 4
Patrick Brown
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
Career Start Year 2004
Number of shared co-authors 5
Giovanni Roti
University of Parma
Career Start Year 2003
Number of shared co-authors 2
Jeffrey W Tyner
Oregon Health & Science University School of Medicine
Career Start Year 2002
Number of shared co-authors 8
Jeffery M Klco
St. Jude Children's Research Hospital
Career Start Year 2000
Number of shared co-authors 12
Xueyuan Cao
University of Chinese Academy of Sciences
Career Start Year 2000
Number of shared co-authors 4
David M Weinstock
Merck & Co.
Career Start Year 1998
Number of shared co-authors 3
Scott C Borinstein
Vanderbilt University Medical Center
Career Start Year 1998
Number of shared co-authors 0
Lukas D Wartman
Washington University School of Medicine in St. Louis
Career Start Year 1998
Number of shared co-authors 0
Brian J P Huntly
University of Cambridge
Career Start Year 1996
Number of shared co-authors 5
Charles G Mullighan
St Jude Children's Research Hospital
Career Start Year 1996
Number of shared co-authors 20
Stefan Fr??hling
German Cancer Research Center (DKFZ), National Center for Tumor Diseases (NCT)
Career Start Year 1996
Number of shared co-authors 5
Kimberly Stegmaier
Dana-Farber Cancer Institute
Career Start Year 1995
Number of shared co-authors 8
Yongjin Li
Mayo Clinic
Career Start Year 1995
Number of shared co-authors 5
Bill H Chang
Oregon Health and Science University
Career Start Year 1993
Number of shared co-authors 7
Timothy A Graubert
Massachusetts General Hospital
Career Start Year 1993
Number of shared co-authors 2
Seishi Ogawa
Kyoto University
Career Start Year 1993
Number of shared co-authors 7
Arndt Borkhardt
Hematology and Clinical Immunology, Heinrich Heine University Dusseldorf
Career Start Year 1992
Number of shared co-authors 6
Scott A Armstrong
Boston Children's Hospital
Career Start Year 1990
Number of shared co-authors 5
Daniel J DeAngelo
Dana-Farber Cancer Institute
Career Start Year 1989
Number of shared co-authors 7
Sima Jeha
St. Jude Children's Research Hospital
Career Start Year 1988
Number of shared co-authors 3
Richard B Lock
Children's Cancer Institute, Lowy Cancer Research Centre, School of Clinical Medicine
Career Start Year 1987
Number of shared co-authors 5
David M Loeb
Children's Hospital at Montefiore.
Career Start Year 1986
Number of shared co-authors 1
Gregory H Reaman
National Cancer Institute
Career Start Year 1978
Number of shared co-authors 6
Alex Look
Dana-Farber Cancer Institute
Career Start Year 1975
Number of shared co-authors 8

Collaborators

James DeGregori
University of Colorado Anschutz Medical Campus
Co-authored papers 11
Kim E Nichols
St. Jude Children's Research Hospital
Co-authored papers 5
Sharon E Plon
Baylor College of Medicine
Co-authored papers 5
Aik Choon Tan
Huntsman Cancer Institute, The University of Utah
Co-authored papers 4
Courtney L Jones
Princess Margaret Cancer Centre, University Health Network
Co-authored papers 4
Michael F Walsh
Memorial Sloan Kettering Cancer Center
Co-authored papers 3
Leila Noetzli
Co-authored papers 3
Vadym Zaberezhnyy
University of Colorado Anschutz Medical Campus
Co-authored papers 3
Jeremy M Boss
Emory University School of Medicine
Co-authored papers 2
Sujatha Venkataraman
Co-authored papers 2
Sarah Scollon
Texas Children's Cancer Center, Texas Children's Hospital
Co-authored papers 2
James L Ross
Co-authored papers 2
Dexiang Gao
University of Colorado Anschutz Medical Campus
Co-authored papers 2
Rajeev Vibhakar
Center for Cancer and Blood Disorders, Children's Hospital Colorado.
Co-authored papers 2
Stephen P Hunger
Children's Hospital of Philadelphia
Co-authored papers 2
Veronica Clavijo Jordan
Harvard Medical School
Co-authored papers 2
Dolores Hambardzumyan
Co-authored papers 2
Chimene Kesserwan
National Institutes of Health
Co-authored papers 1
Jinghui Zhang
Changhai Hospital, Second Military Medical University
Co-authored papers 1
Katherine L Nathanson
Perelman School of Medicine, University of Pennsylvania, USA Abramson Cancer Center
Co-authored papers 1
Franck Bourdeaut
SIREDO Oncology Center, Institut Curie Hospital, and Universite de Paris
Co-authored papers 1
David Wu
University of Washington
Co-authored papers 1
Lucy A Godley
The University of Chicago
Co-authored papers 1
Louise C Strong
University of Texas MD Anderson Cancer Center
Co-authored papers 1
Greg S Martin
Emory University School of Medicine
Co-authored papers 1
Anupriya Agarwal
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 1
Daniel A Pollyea
University of Colorado Division of Hematology
Co-authored papers 1
Jonathan M Marron
and Center for Bioethics, Harvard Medical School
Co-authored papers 1
Michael Chicka
Co-authored papers 1
Mark J Routbort
University of Texas MD Anderson Cancer Center
Co-authored papers 1
Release 1.2